Albiglutide Albumin Fusion: Comprehensive Peptide Reference
Albumin-GLP-1 fusion protein providing once-weekly GLP-1 receptor agonism through non-covalent albumin binding. Covers molecular mechanisms, biological activ...
Chemical Identity
| Property | Value |
|---|---|
| Chemical Formula | Recombinant fusion protein |
| Molecular Weight | ~73 kDa |
| CAS Number | 804747-34-4 |
| Product Name | Tanzeum (discontinued) |
| Peptide Class | Albumin-GLP-1 Fusion |
Structure
Albiglutide fuses a modified GLP-1(7-36) sequence to recombinant human albumin. The large molecular size (~73 kDa) reduces renal clearance while albumin binding properties extend circulation time.
Clinical Applications
Was approved for type 2 diabetes as Tanzeum (2014). Discontinued by GlaxoSmithKline in 2018 for commercial reasons.
Pharmacokinetics
- Half-life: ~5 days
- Dosing: Once weekly subcutaneous
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Albiglutide Albumin Fusion” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Albiglutide Albumin Fusion: Comprehensive Peptide Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept